Transvenous implantable defibrillators and cardiac resynchronization devices placed for primary prevention of sudden death and as a heart failure therapy for advanced systolic dysfunction in association with bundle branch block are now common therapies. Outside of clinical trials, long-term mortality outcomes are unknown. Additionally, newer-generation devices are enabled to transmit data daily from patients' homes with the use of a remote communicator, and these data are available to physicians on the Internet. This study provides 1-and 5-year survival outcome data in Ͼ194 000 device recipients with devices implanted from a single manufacturer and demonstrates that survival is equivalent to those patients studied in the pivotal randomized trials. One-and 5-year implantable cardioverter-defibrillator survival rates are 92% and 68%, respectively, and are 88% and 54% for cardiac resynchronization therapy defibrillators. Patients transmitting data remotely had the best survival, and shock therapies were associated with worsened survival in both implantable defibrillator and cardiac resynchronization device recipients. The 1-and 5-year risks of shock were 14% and 38% for implantable cardioverter-defibrillator recipients and were 13% and 33% for cardiac resynchronization therapy defibrillator subjects. Sensitivity analysis did not detect a significant imbalance between patients followed in traditional clinic settings compared with those transmitting data remotely as well as in the clinic. This is the largest report to date on survival after device implantation and finds that survival benefits observed over shorter follow-up intervals in clinical trials are maintained. This information is particularly important because there are upfront risks and costs associated with device implantation.
Relations of Biomarkers of Distinct Pathophysiological Pathways and Atrial Fibrillation Incidence in the Community
Summary: The prevalence of atrial fibrillation (AF) is expected to increase owing to an aging population, improved therapies, and longer survival with heart disease. Many pathophysiological pathways have been examined in animal and human studies within the context of AF. We report the prospective association of a broad panel of blood and urinary biomarkers representing inflammation (Creactive protein and fibrinogen), neurohormonal activation (B-type natriuretic peptide and N-terminal proatrial natriuretic peptide), oxidative stress and endothelial dysfunction (homocysteine), the renin-angiotensin-aldosterone system (renin and aldosterone), thrombosis (D-dimer and plasminogen activator inhibitor), and microvascular damage (urinary albumin excretion) in a community-based cohort with long-term incidence of AF. A recently published risk score for long-term incidence of AF combines several wellestablished clinical risk factors for AF such as age, sex, body mass index, hypertension, and cardiovascular disease, including valvular disease and heart failure. We tested the predictive value of the strongest biomarkers in addition to the clinical variables combined in the risk algorithm. The neurohormone B-type natriuretic peptide and the inflammatory biomarker C-reactive protein revealed significant associations with outcome in multivariable-adjusted analyses. B-type natriuretic peptide was the strongest single biomarker in relation to AF occurrence and significantly improved risk prediction based on the risk algorithm. Whether determination of B-type natriuretic peptide contributes to strategies to prevent AF must be established in future studies. Our findings may also provide valuable insights into the pathophysiology of AF.
Conclusions: B-type natriuretic peptide (BNP) is a predictor of incident AF and improves risk stratification based on wellestablished clinical risk factors. Whether knowledge of BNP concentrations may be used to target individuals at risk of AF for more intensive monitoring or primary prevention requires further investigation. 6 
Funny Current Downregulation and Sinus Node Dysfunction Associated With Atrial Tachyarrhythmia: A Molecular Basis for Tachycardia-Bradycardia Syndrome
Summary: Sinoatrial node dysfunction is frequently associated with atrial tachyarrhythmias, and patients with the combination are said to suffer from the relatively common tachycardia-bradycardia syndrome. Abnormalities in sinus node pacemaker function on termination of atrial tachyarrhythmias such as atrial fibrillation can cause syncope and require pacemaker implantation, but the underlying mechanisms remain poorly understood. There is evidence from clinical and experimental studies that suggests that a significant component of sinus node dysfunction in patients with the tachycardia-bradycardia syndrome may actually be caused by supraventricular tachyarrhythmia and may be reversible if the tachyarrhythmia is controlled. The present study examined the hypothesis that very rapid atrial tachyarrhythmias can cause ion channel downregulation in the sinus node, thereby causing abnormal sinus node function. Dogs subjected to atrial tachypacing at 400 bpm for 7 days showed prolonged sinus node recovery time, which indicates sinus node dysfunction. Ion channel subunit messenger RNA expression was measured in sinus node tissue and showed downregulation by atrial tachycardia of 2 specific types of subunits: Those underlying the funny current, which is known to be particularly important in cardiac pacemaking activity, and an accessory subunit involved in the slow delayed-rectifier K ϩ channel. Patchclamp studies on sinus node cells isolated from control dogs and dogs subjected to atrial tachypacing confirmed the specific downregulation of funny current and slow delayed-rectifier K ϩ current with atrial tachycardia. These alterations were incorporated in a mathematical model of sinus node electric activity, which suggested that the funny current changes were the principal factor in sinus node suppression by atrial tachycardia. Our results provide insights into the molecular mechanisms underlying clinically significant bradycardic complications of this common and important clinical syndrome.
Conclusions: Atrial tachycardia downregulates sinoatrial node (SAN) hyperpolarization-activated cyclic nucleotide-gated subunits (HCN2/4) and minK subunit expression, along with the corresponding currents I f and I Ks . Tachycardia-induced remodeling of SAN ion channel expression, particularly for the "pacemaker" subunit I f , may contribute to the clinically significant association between SAN dysfunction and supraventricular tachyarrhythmias. 7
Relationship of Paroxysmal Atrial Tachyarrhythmias to Volume Overload: Assessment by Implanted Transpulmonary Impedance Monitoring
Summary: Atrial tachyarrhythmias (AT), particularly atrial fibrillation (AF), occur frequently in patients with heart disease and left ventricular dysfunction. Clinical experience suggests that AT/AF susceptibility is increased during periods of worsening heart failure, a condition typically associated with excess fluid volume in the lungs. However, the apparently close association between heart failure and AT/AF has been established primarily during follow-up of patients with chronic disease; documenting such a relationship in acute settings of heart failure exacerbation in free-living individuals is much more difficult. Recently, however, certain implantable cardioverter-defibrillators are capable of not only tracking onset and duration of AT/AF episodes but also estimating transpulmonary electric bioimpedance as an index of intrathoracic fluid volume status. Using this recently introduced technology, findings in this study support the view that there is a clinically important association between worsening pulmonary fluid volume status (as assessed by diminishing transpulmonary electric bioimpedance) and increased susceptibility to AT/AF events in free-living individuals. In addition, our findings suggest that AT/AF episodes may be an underappreciated but an important trigger for acute pulmonary congestion/volume overload. Potentially, if larger studies substantiate the relationships observed here, a treatment strategy designed to reduce AT risk and/or detect and foreshorten AT episodes may prove beneficial for reducing susceptibility to pulmonary congestion in certain patients with heart failure.
Conclusions: These findings not only support the view that worsening pulmonary congestion is associated with increased AT frequency in patients with left ventricular dysfunction but also suggest that AT events may be responsible for triggering episodic pulmonary congestion more often than previously suspected. 8 
Periprocedural Stroke and Management of Major Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The Impact of Periprocedural Therapeutic International Normalized Ratio
Summary: Periprocedural thromboembolic and hemorrhagic events are complications of percutaneous radiofrequency catheter ablation of atrial fibrillation. The management of anticoagulation before and after radiofrequency catheter ablation could play an important role in the prevention of these complications. The incidence of thromboembolic events varies from 1% to 5%, depending on the ablation and the anticoagulation strategy used in the periprocedural period. At present, although discontinuation of warfarin 3 to 5 days before ablation with and without bridging with low-weight heparin is the most frequently implemented protocol, the optimal anticoagulation management (minimizing thromboembolism while not increasing hemorrhagic complications) is not well established. We first reported radiofrequency catheter ablation of atrial fibrillation without discontinuation of warfarin. This is the first large series of patients undergoing ablation of atrial fibrillation with different anticoagulation protocols and with different ablation catheters showing that the continuation of therapeutic warfarin during the procedure (radiofrequency catheter ablation) reduces the risk of periprocedural stroke/ transient ischemic attack without increasing the risk of hemorrhagic events. Of interest, this anticoagulation protocol eliminates the need for a preprocedural transesophageal echocardiogram. A randomized controlled trial is necessary to confirm the results of our study.
Conclusion:
The combination of an open irrigation ablation catheter and periprocedural therapeutic anticoagulation with warfarin may reduce the risk of periprocedural stroke without increasing the risk of pericardial effusion or other bleeding complications. 9
Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial
Summary: Atrial fibrillation (AF) occurring after cardiac surgery is common and is associated with considerable morbidity. Early restoration of sinus rhythm is usually desirable, and pharmacological conversion is generally preferable to electric cardioversion in these early postoperative patients. Intravenous vernakalant, a new antiarrhythmic agent with atrial selective properties, has been shown to be effective in rapidly and safely converting approximately 50% of patients with new-onset AF. In this study, vernakalant demonstrated successful conversion of AF to sinus rhythm in 47% of patients with new-onset AF after cardiac surgery. Responders converted rapidly (median time, 12 minutes). Vernakalant was ineffective at converting a small number of patients (nϭ6) with new-onset atrial flutter. Two serious adverse events occurred during the initial 10-minute vernakalant infusion. One event of hypotension responded to discontinuation of the infusion, intravenous fluids and norepinephrine, resolving in 3 minutes. The other event was complete heart block that responded to discontinuation of the infusion and pacing through an epicardial wire (placed at the time of surgery), resolving in 12 minutes. Vernakalant does not appear to promote ventricular arrhythmia. Episodes of asymptomatic, nonsustained ventricular runs were captured on Holter monitoring in all patients given vernakalant or placebo. There were no episodes of torsades de pointes, ventricular fibrillation, or death. Vernakalant is potentially a safe and effective pharmacological alternative for the conversion of AF to sinus rhythm in patients after cardiac surgery.
Conclusions:
Vernakalant was safe and effective in the rapid conversion of AF to sinus rhythm in patients who had AF after cardiac surgery. 10
Utility of Treadmill Testing in Identification and Genotype Prediction in Long-QT Syndrome
Summary: Long QT syndrome (LQTS) is a leading cause of sudden death in children and adolescents. Excellent outcomes in the management of LQTS can be achieved with lifestyle modifications and therapeutic intervention, highlighting the importance of its identification. Although genetic testing remains the diagnostic "gold standard," the diagnosis of LQTS remains challenging when electrocardiographic findings are borderline, which can occur in up to 50% of cases. In this article, we sought to develop a provocative exercise testing strategy to unmask the LQT phenotype and help guide genetic testing. We found that QTc prolongation when comparing lying with standing at the beginning of exercise testing was useful in identifying LQTS patients [Pϭ0.029]. Comparing exercise with recovery QT intervals, increased QT hysteresis was suggestive of LQT2 genotype [Pϭ0.0022]. Failed QT shortening at peak exercise identified LQT1, similar to previous reports. The area under the ROC curve for identifying LQTS from postural QTc change was 0.666 (Pϭ0.0095), and for predicting LQT2 from hysteresis, it was 0.825 (PϽ0.0001). Postural QTc increase was Ͼ30 ms in 68% of "concealed" LQTS patients, and QT hysteresis was Ͼ25 ms in 67% of concealed LQT2 patients. A simple postural test in combination with comparison of exercise and recovery QTs is useful in identifying LQTS and predicting genotype. These findings may be useful in directing genetic testing.
Conclusions:
The presence and genotype of LQTS can be predicted by a combination of postural and exercise changes in the QT/RR relationship. Beta-Blockade normalized these changes. Routine exercise testing is useful in predicting and directing genetic testing in LQTS. 11
Risk Factors for Mortality in Patients With Cardiac Device-Related Infection
Summary: Because of the increased use of pacemakers and implantable cardioverter defibrillators in medical practice, cardiac device infection (CDI) has become a complication with significant mortality. Although recent studies have identified clinical characteristics for developing CDI, risk factors for mortality have yet to be determined. The purpose of the present study was to establish risk factors associated with mortality in a large study population of 210 patients with CDI. In our cohort, 6-month all-cause mortality was 18% with major causes of death including sepsis and cardiac arrest. After adjusting for age, sex, and treatment strategy, independent variables associated with death were systemic embolization, moderate or severe tricuspid regurgitation, abnormal right ventricular function, and abnormal renal function. Interestingly, size and mobility of device vegetations were not clinical predictors of increased mortality. The presence of these clinical risk factors target patients with CDI who are at high-risk for mortality and may benefit from more aggressive evaluation.
Conclusions:
We identified several clinical and echocardiographic variables that identify patients with cardiac-device related infection who are at high-risk for mortality and may benefit from more aggressive evaluation. 12
Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia
Summary: Arrhythmogenic right ventricular cardiomyopathy/dysplasia is an inheritable heart muscle disease with a natural history that is related predominantly to sudden death, mostly in young people. There is general agreement that an implantable cardioverterdefibrillator (ICD) is indicated in arrhythmogenic right ventricular cardiomyopathy/dysplasia patients who survived an episode of ventricular fibrillation or sustained ventricular tachycardia, whereas prophylactic ICD therapy in patients with no history of sustained tachyarrhythmias or cardiac arrest is still an unsolved issue. There is a tendency to implant an ICD once the disease has been diagnosed, regardless of symptoms or life-threatening ventricular arrhythmias. Hence, a growing cohort of young arrhythmogenic right ventricular cardiomyopathy/dysplasia patients such as asymptomatic relatives and healthy gene carriers who are identified by cascade family screening may undergo unnecessary ICD implantations with significant economic costs and quality-of-life concerns. The present multicenter study assessed the long-term outcome and determinants of ICD therapy in a large arrhythmogenic right ventricular cardiomyopathy/dysplasia population with no prior ventricular fibrillation or sustained ventricular tachycardia. The study results suggest that ICD implantation is as necessary in patients with a history of syncope as it is in those who suffer arrhythmic cardiac arrest. However, prophylactic ICD implantation may not be justified in asymptomatic patients regardless of family history of sudden death or results of programmed ventricular stimulation because of their favorable long-term outcome. Programmed ventricular stimulation, traditionally used to stratify the risk of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients without spontaneous ventricular tachyarrhythmias, is of limited value in predicting appropriate ICD interventions and should not be used as a routine prognostic strategy.
Conclusions:
One fourth of patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior sustained ventricular tachycardia or VF had appropriate ICD interventions. Syncope was an important predictor of life-saving ICD intervention and is an indication for ICD. Prophylactic ICD may not be indicated in asymptomatic patients because of their low arrhythmic risk regard-less of familial sudden death and programmed ventricular stimulation findings. Programmed ventricular stimulation had a low predictive accuracy for ICD therapy. 13
Visually-Guided Balloon Catheter Ablation of Atrial Fibrillation: Experimental Feasibility and First-in-Human Multicenter Clinical Outcome
Summary: Catheter-based electric isolation of the pulmonary veins can successfully treat patients with paroxysmal atrial fibrillation. Although conceptually straightforward, its clinical application has been hindered by important technical hurdles related to the complexity and patient-to-patient variability of pulmonary venous anatomy, as well as the difficulty in sequentially positioning the ablation catheter in a point-by-point contiguous fashion to isolate the veins. These considerations have led to the development of a balloon ablation catheter equipped with an endoscope that allows direct visualization of the atrial-venous junction and an easily maneuverable optical fiber that projects an arc of ablative laser energy (980 nm) onto the tissue in contact with the balloon face. This novel endoscopic ablation system was used in a series of preclinical porcine experiments and a first-in-human multicenter clinical study. The former demonstrated the feasibility to electrically isolate the pulmonary veins both immediately and persistently. In the clinical phase, a total of 30 patients with paroxysmal atrial fibrillation were treated. In the short term, Ͼ90% of the veins were successfully isolated with the balloon system. Long term, the 12-month drug-free freedom from atrial fibrillation after a single procedure was 60%. This study establishes the feasibility for this novel paradigm of catheter ablation of atrial fibrillation. Instead of relying on indirect cues to the location of the ablation catheter in relation to the pulmonary venous anatomy, endoscopic visualization permits the operator to directly visualize the tissue being targeted for ablation, an approach moving ever so closer to approximating the surgical experience.
Conclusion: This study establishes the feasibility of a novel paradigm for AF ablation: direct visualization to guide catheter ablation of the left atrial-PV junction. 14
Electrophysiological Effects of Late Percutaneous Coronary Intervention for Infarct-Related Coronary Artery Occlusion: The Occluded Artery Trial-Electrophysiological Mechanisms (OAT-EP)

Summary:
The late open artery hypothesis posits that clinical outcomes can be improved by late opening of persistently occluded infarct-related arteries during the subacute phase of myocardial infarction, when myocardial salvage is not anticipated. Several mechanisms have been proposed for the putative benefit of late reperfusion, including stabilization of the electrophysiological substrate and downstream prevention of malignant ventricular arrhythmias. This ancillary study of the Occluded Artery Trial evaluated the effects of late opening and stenting of an occluded infarct artery on several noninvasive measures of electrophysiological stability during the first year after myocardial infarction. Heart rate variability, assessing the autonomic nervous system, was the primary measure. Major secondary measures evaluated repolarization (dynamic changes in T-wave morphology [T-wave variability]) and delayed myocardial conduction (filtered QRS duration on the signal-averaged ECG). Compared with medical therapy alone, late reperfusion and stenting of a persistently occluded infarct-related artery did not change heart rate variability, filtered QRS, or T-wave variability during the first year after myocardial infarction. These results are consistent with the lack of clinical benefit, including no reduction in sudden death, with PCI for stable patients with persistently occluded infarct-related arteries after myocardial infarction in the main Occluded Artery Trial.
Conclusions: PCI with stenting of a persistently occluded infarctrelated artery during the subacute phase after myocardial infarction compared with medical therapy alone had no significant effect on changes in heart rate variability, the time-domain signal-averaged ECG, or T-wave variability during the first year after myocardial infarction. These findings are consistent with the lack of clinical benefit, including no reduction in sudden death, with PCI for stable patients with persistently occluded infarct-related arteries after myocardial infarction in the main OAT. 15
Ryanodine Receptor Phosphorylation by Calcium/Calmodulin-Dependent Protein Kinase II Promotes Life-Threatening Ventricular Arrhythmias in Mice With Heart Failure
Summary: Despite recent therapeutic advances including ␤-adrenergic blockers and implantable cardioverter-defibrillators, ventricular arrhythmias remain a prominent cause of death in patients with heart failure. Diastolic Ca 2ϩ leak from the sarcoplasmic reticulum is believed to contribute to arrhythmia initiation in failing hearts, although the underlying mechanisms remain poorly understood. The expression and activity of the enzyme Ca 2ϩ /calmodulindependent protein kinase II (CaMKII) are upregulated in heart failure. Although increased CaMKII activity has been implicated in arrhythmogenesis, the specific CaMKII targets contributing to arrhythmia susceptibility have remained elusive. Our data revealed that mice in which the CaMKII phosphorylation site on the cardiac ryanodine receptor is constitutively activated exhibit an increased likelihood of intracellular Ca 2ϩ releases. This diastolic Ca 2ϩ "leak" leads to an increased susceptibility to ventricular tachycardia in mice. Moreover, constitutive CaMKII phosphorylation of ryanodine receptor caused an increase in arrhythmogenic sudden cardiac deaths after induction of experimental heart failure. Conversely, mice with genetic ablation of the CaMKII site on ryanodine receptor exhibited protection from induced ventricular arrhythmias due to heart failure. Taken together, our studies suggest that CaMKII phosphorylation of ryanodine receptor is an important downstream target of CaMKII that could be exploited therapeutically to minimize arrhythmia susceptibility in heart failure. Future studies utilizing pharmacological inhibition of this signaling event, once tested, may be a new avenue for reducing risk of sudden death in patients with heart failure.
Conclusions:
Our results suggest that Ca 2ϩ /calmodulin-dependent protein kinase II phosphorylation of RyR2 Ca 2ϩ release channels at S2814 plays an important role in arrhythmogenesis and sudden cardiac death in mice with heart failure. 16
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study
Summary: The clinical importance of atrial tachyarrhythmia (AT) episodes or atrial fibrillation (AF) detected by pacemakers and implantable cardioverter-defibrillators is currently unknown. In the practice of cardiology today, arrhythmia management devices are being implanted in increasing numbers of patients. With the increasing prevalence of these sophisticated devices, clinicians are confronted with accurate, quantitative and comprehensive memory for AT/AF events. Current evidence-based cardiology practice defines management strategies for AT/AF that is detected by conventional monitoring techniques, but these techniques are sensitive only for episodes that are frequent, prolonged, and/or symptomatic. It remains unknown if the same management strategies apply to brief and often asymptomatic episodes of AT/AF. In the research presented here, we made the first attempt to answer a question encountered frequently in pacemaker/implantable cardioverter-defibrillator clinics: Is there a critical level of AT/AF burden that increases the risk of thromboembolic events that is independent of other known risk factors? The data, although not definitive, suggest that there is such a quantitative relationship between AT/AF burden and thromboembolic events. Further research will improve the precision of the current estimate and define the impact of intervention with antithrombotic therapy.
Conclusions:
The thromboembolic event (TE) rate was low compared with patients with traditional AF with similar risk profiles. The data suggest that TE risk is a quantitative function of AT/AF burden. AT/AF burden Ն5.5 hours on any of 30 prior days appeared to double TE risk. Additional studies are needed to more precisely investigate the relationship between stroke risk and AT/AF burden. 17
A Prospective Comparison of Cardiac Imaging Using Intracardiac Echocardiography With Transesophageal Echocardiography in Patients With Atrial Fibrillation: The Intracardiac Echocardiography Guided Cardioversion Helps Interventional Procedures Study
Summary: Interventions in atrial fibrillation (AF) are evolving rapidly from long-standing methods such as cardioversion to new ones such as septal closure devices, left atrial appendageal occlusion, and AF ablation. Imaging is vital to the performance of these therapeutic procedures. Efficient imaging in the cardiac catheterization laboratory is of interest to all healthcare service providers worldwide. The availability of catheter-based ultrasound imaging is an important technology, and its comparison to widely used approaches such as transesophageal echocardiography (TEE) is an essential element of its assessment. This report provides the results of the first prospective, controlled, multicenter study performed with intracardiac echocardiography (ICE). The ICE technique is compared to TEE in patients with AF and is an important first step toward evidence-based assessment of these technologies in a major cardiac population. The study provides a critical analysis of the imaging capabilities of both ICE and TEE in this patient population, highlights areas of concordance and discordance between the techniques, and provides a realistic assessment of expectation of use of both techniques during interventional and electrophysiological procedures. Limitations of ICE, which are important to note for refinement of this technique, can be elicited from this study. From the data, we can conclude that this study provides validation for the use of ICE for left atrial and interatrial septal imaging. ICE imaging is less sensitive compared to TEE for left atrial appendageal thrombus identification.
Conclusions:
This study provides validation for the use of ICE for left atrium and interatrial septal imaging. ICE imaging was less sensitive compared to TEE for LAA thrombus identification. 18
Epicardial Substrate and Outcome With Epicardial Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
Summary: Myocardial involvement in arrhythmogenic right ventricular cardiomyopathy/dysplasia appears to progress from epicardium to endocardium. Catheter ablation of ventricular tachycardia (VT) from the endocardium may be limited by epicardial VT substrate/ circuits, right ventricular thickening, or both. Percutaneous epicardial mapping and ablation were performed in 13 consecutive patients with right ventricular cardiomyopathy/dysplasia after failed endocardial VT ablation. Low-voltage areas consistent with scar were more extensive on the epicardium than the endocardium and uniformly included wide, split, and late electrograms consistent with abnormal conduction. Transmural thickness at the base of the right ventricle was Ͼ10 mm in 6 of the 13 patients. Twenty-seven distinct VTs were targeted for ablation from the epicardium; epicardial ablation sites were often opposite endocardial sites with normal voltage or where ablation had been ineffective. During follow-up, 77% of patients were free of VT. These findings suggest that failed endocardial ablation of VT in patients with right ventricular cardiomyopathy/dysplasia is often due to epicardial VT origins. Percutaneous epicardial mapping and ablation can improve outcomes in these patients.
Conclusions:
Patients with right ventricular cardiomyopathy/dysplasia and VT after endocardial ablation have a more extensive epicardial area of electrogram abnormalities and frequently have basal right ventricular wall thickening. Epicardial substrate and VT mapping identifies targets, and ablation results in VT control. 19 
Intracellular Calcium Dynamics and Acceleration of Sinus Rhythm by ␤-Adrenergic Stimulation
Summary: For many years we were taught that membrane ionic currents, such as I f , are responsible for sinus node automaticity. The rhythmic membrane depolarization (membrane ionic clock) then initiates sarcoplasmic reticulum (SR) calcium release and cardiac contraction. In that scenario, the SR Ca release is responsible only for the mechanical function of the heart. However, the findings in the present study and in several previous studies indicate that rhythmic and spontaneous (nonvoltage-gated) SR Ca release (Ca clock) is also important in sinoatrial node automaticity and is largely responsible for sinus rate acceleration during sympathetic stimulation. The Ca and the membrane ionic clocks work synergistically to generate sinus rhythm. Because healthy SR Ca handling is important in the initiation of the heartbeats, disease conditions associated with abnormal SR Ca handling and impaired intracellular Ca dynamics may be associated with sinoatrial node dysfunction. Clinical examples may include heart failure, chronic atrial fibrillation, and genetic mutations of the type 2 ryanodine receptor. The latter disease is associated with both catecholaminergic polymorphic ventricular tachycardia and sinus bradycardia. Abnormally low SR Ca release threshold and chronic SR Ca depletion may be responsible for both tachycardic and bradycardic components of disease. Recently, animal experiments suggest that inhibition of spontaneous SR Ca release is effective in arrhythmia control. Data from the present study suggest that clinical trials of these therapeutic strategies should consider sinus node dysfunction, such as bradycardia and chronotropic incompetence, as possible complications.
Conclusions: Acceleration of the Ca 2ϩ clock in the superior SAN plays an important role in sinus acceleration during ␤-adrenergic stimulation, interacting synergistically with the voltage clock to increase sinus rate. 20
Cost-Effectiveness of Radiofrequency Catheter Ablation Compared With Antiarrhythmic Drug Therapy for Paroxysmal Atrial Fibrillation
Summary: Studies of selected patients with atrial fibrillation have shown that a clinical strategy involving radiofrequency catheter ablation results in a higher likelihood of remaining in sinus (normal) rhythm than a strategy of using only antiarrhythmic drugs, along with greater improvements in quality of life. Catheter ablation, however, is an expensive procedure; therefore the added costs of catheter ablation must be weighed against the proven benefits before this strategy can be endorsed on a widespread basis. In the current study, we created a disease simulation model (Markov model) to assess the cost-effectiveness of radiofrequency catheter ablation, compared with continued antiarrhythmic drug therapy without ablation, for patients with paroxysmal atrial fibrillation. The model projected likely outcomes for each treatment over a period of 5 years, based on previously published studies, as well as analysis of some newly collected quality-of-life data. We found that the initial extra costs of ablation are partly offset over time by a reduced need for repeat episodes of care for atrial fibrillation and that the radiofrequency catheter ablation strategy was associated with slightly better quality-adjusted life expectancy over this time frame. Combining these findings resulted in a cost-effectiveness ratio of Ϸ$51 000 per quality-adjusted life-year gained, a value generally considered acceptable within the US health care system.
Conclusions: Radiofrequency ablation with/without antiarrhythmic drug (AAD) for symptomatic, drug-refractory paroxysmal AF appears to be reasonably cost-effective compared with AAD therapy alone from the perspective of the US health care system, based on improved quality of life and avoidance of future health care costs. 21
Termination of Atrial Fibrillation Using Pulsed Low-Energy Far-Field Stimulation
Summary: This study tested whether low-amplitude shocks delivered via 2 field electrodes were capable of terminating atrial fibrillation in isolated perfused canine atria. Our expectation was that the fields induced by the 2 physical electrodes would create many "virtual" electrodes that could then be used to overdrive-pace the fibrillating tissue and thereby terminate fibrillation. The observation that this method, which we call far-field antifibrillation pacing, converted atrial fibrillation reliably (93% success rate) with the use of field strengths that were only 13% of the energy required to cardiovert with a single shock suggests that this method may have clinical utility. Cardioversion of atrial fibrillation with the use of lower energies could reduce the pain and tissue damage associated with a large single shock and prolong the battery life of implantable devices. Further experimental studies are needed, however, to optimize the shock protocol and to determine whether far-field antifibrillation pacing is effective and safe in vivo.
Conclusions: AF in our model can be terminated by far-field antifibrillation pacing with only 13% of the energy required for cardioversion. Further studies are needed to determine whether this marked reduction in energy can increase the effectiveness and safety of terminating atrial tachyarrhythmias clinically. 22
Efficacy and Safety of Automatic Remote Monitoring for Implantable Cardioverter-Defibrillator Follow-Up: The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) Trial
Summary: Cardiac implantable electronic devices are increasing in prevalence. Postimplantation follow-up is important for monitoring both device function and patient condition. Currently, follow-up care follows guidelines that lack supporting data, leading to inconsistent clinical practice. Conventional in-person evaluation, if performed every 3 to 6 months, generates a huge clinical burden, but its efficacy with regard to patient safety, adherence, incidence of unscheduled encounters, and rate of problem detection remains untested. The absence of monitoring between hospital interrogations permits potentially important clinical data to remain concealed. Remote monitoring technology incorporated into devices holds the promise of resolving these problems. The Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST) trial in patients with defibrillators confirmed significant limitations of conventional care but, in contrast, affirmed the safety, efficacy, and early warning capability (ie, within 24 hours) of automatic remote monitoring. The outcome measure of hospital use was reduced by almost 50% compared with conventional care. The alert capability and archiving power of this remote management system suit it for system performance monitoring and management of devices placed under advisory notices. The results are important for heart failure patients in whom continuous surveillance with the ability to self-declare parameter deviations may permit early clinical intervention. The trial results have significant implications for the management of patients receiving implantable electronic cardiac devices. . Although these results should not preclude women from receiving ICDs, efforts are needed to understand the reasons for higher ICD implantation-related adverse event rates in women and to develop strategies to reduce the risk of these events.
Conclusions: Women are more likely than men to have in-hospital adverse events related to ICD implantation. Efforts are needed to understand the reasons for higher ICD implantation-related adverse event rates in women and to develop strategies to reduce the risk of these events. 24
Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?: Data From the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry
Summary:
The key therapies for long-QT syndrome (LQTS) are ␤-blockers, left cardiac sympathetic denervation (LCSD), and the implantable cardioverter-defibrillator (ICD). The ICD, despite concerns about complications in the young, is being used in a growing number of patients. There are no adequate data on the patient characteristics associated with ICD implantation in clinical practice and on their outcome. We initiated a largely European LQTS ICD Registry. Among the 233 patients enrolled and with a mean follow-up close to 5 years, there was an excess of female patients and of LQT3 patients. Unexpectedly, 9% of the patients were asymptomatic when they received an ICD. Appropriate shocks were received by 28% of patients; adverse events occurred in 25%. We developed a scoring system based on simple, easily available clinical variables to verify possible prediction of appropriate shocks. These were predicted by age Ͻ20 years at implantation, a QTc Ͼ500 milliseconds, prior cardiac arrest, and cardiac events despite therapy; within 7 years, appropriate shocks occurred in no patients without any of these variables and in 70% of those with all of them. Our data suggest how to identify logical candidates for ICD implantation and indicate that some specific programming features may decrease the rate of unnecessary shocks. The relatively high incidence of complications within 5 years in a relatively young population calls for a reassessment of the criteria for implanting ICDs in LQTS patients.
The proposed risk scoring system may increase the probability of a rational decision, balancing safety with quality of life.
Conclusions: Reflecting previous concepts, ICDs were implanted in some LQTS patients whose high risk now appears questionable. Refined criteria for implantation, reassessment of pros and cons, ICD reprogramming, and consideration for other existing therapeutic options are necessary. 25
Serum Long-Chain n-3 Polyunsaturated Fatty Acids and Risk of Hospital Diagnosis of Atrial Fibrillation in Men
Summary: Fish consumption has been associated with reduced risk of atrial fibrillation (AF) and the long-chain n-3 polyunsaturated fatty acids (PUFAs) in fish have been suggested to account for the beneficial effects. The present study assessed the relationship between serum concentrations of long-chain n-3 PUFAs eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA), which also serve as a marker of fish or fish oil consumption, and risk of AF in middle-aged or older men in Eastern Finland. During 17.7 years of follow-up, 240 men from the total cohort of 2174 men experienced an AF event that required hospitalization. Men in the highest quartile of serum EPAϩDPAϩDHA had a 35% lower risk of AF compared with men in the lowest quartile. Of the individual fatty acids, only serum DHA was associated with the risk, with a 38% lower risk in the highest quartile. No association with the risk was found with serum intermediate chain-length n-3 PUFA, ␣-linolenic acid, not even when the serum EPAϩDPAϩDHA concentration was low. Although previous studies in this study population have shown an association between long-term low-level mercury exposure and risk of cardiovascular diseases, high mercury concentration in hair was not associated with the risk of AF in this study. In summary, long-chain n-3 PUFAs, and especially DHA, may be effective in reducing the risk of AF in men.
Conclusions: An increased concentration of long-chain n-3 PUFAs in serum, a marker of fish or fish oil consumption, may protect against AF. Serum docosahexaenoic acid concentration had the greatest impact. 26
Coronary Artery Injury Due to Catheter Ablation in Adults: Presentations and Outcomes
Summary: Coronary artery injury is a rare but important complication after catheter ablation. In this study we report 4 patients (0.09%) who sustained a coronary injury of a cohort of patients undergoing 4655 ablation procedures. Coronary injury occurred in 3 patients after radiofrequency ablation, and a moderate asymptomatic stenosis occurred after cryoablation in the other patient. Branches of the right coronary artery were involved in all cases. There is a spectrum of presentations of coronary injury after ablation procedures. Acute occlusion of the artery was seen in 2 patients. Coronary stenting appears to be required for acute occlusion that does not respond to nitroglycerin but may be complicated by the phenomenon of coronary no-reflow. Although the majority of coronary injuries present acutely, delayed presentations of up to 2 weeks may also occur. Coronary arteries appear to be particularly susceptible to injury from ablation in the epicardium and the middle cardiac vein. Unanticipated anatomic variation may also predispose to coronary injury. Awareness of these features should help with the risk/benefit assessment for ablation in locations where coronary arteries are at risk. Coronary injury must be considered in patients who develop persistent chest discomfort, especially if ablation occurs in areas adjacent to the coronary circulation.
Conclusions: Coronary arterial injury after ablation procedures is rare. It may present acutely or several weeks after an ablation procedure. Acute occlusion appears to require coronary stenting. Unanticipated anatomic variations can predispose to coronary injury. 27 The Editors Most Read in Arrhythmia and Electrophysiology II e267
Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population
Summary: Faster heart rate (HR) has been associated with all-cause mortality, sudden death, and other adverse outcomes in the general population and in patients with heart disease. The relationship between intrinsic (unpaced) HR, continuously measured by an implanted device, and clinical outcomes was assessed in a large implantable cardioverter-defibrillator population. In these subjects, higher HR was associated with greater risk of death or heart failure hospitalization, with those patients exhibiting a mean HR Ͼ90 bpm experiencing almost a 4-fold difference in events compared with those patients with mean HR Ͻ75 bpm. For patients with implantable cardioverter-defibrillators, HR data can predict outcomes in patients with implantable cardioverter-defibrillators. Beta-Blockers appear to reduce events in a direct relationship to HR. Access to HR trends in patients with implantable cardioverter-defibrillators may assist clinical decision making. HR remains an underutilized, but easily determined, and important clinical predictor in this population.
Conclusions:
In this ICD population, the mean intrinsic HR was strongly associated with outcomes. 28
Epicardial Border Zone Overexpression of Skeletal Muscle Sodium Channel SkM1 Normalizes Activation, Preserves Conduction, and Suppresses Ventricular Arrhythmia: An In Silico, In Vivo, In Vitro Study
Summary: Reentry accounts for Ϸ85% of serious tachyarrhythmias complicating ischemic heart disease. Current antiarrhythmic therapies attempt to prevent or treat these arrhythmias by creating bidirectional conduction block, prolonging refractoriness, or both in combination. Implantable defibrillators have had great success in terminating sustained ventricular tachyarrhythmias. However, these therapies possess drawbacks ranging from incomplete arrhythmia suppression to overt toxicity, including proarrhythmia, and the psychological consequence of painful and sometimes inappropriate defibrillation. A key contributor to many reentrant arrhythmias is slow conduction within part of the reentrant circuit such as a myocardial infarct epicardial border zone. We tested the hypothesis that preserving or speeding conduction through the depolarized surviving myocytes within the border zone would be antiarrhythmic. We focally introduced an adenovirus expressing a skeletal muscle sodium channel (SkM1) that mathematical modeling indicated would operate more efficiently at depolarized membrane potentials than the native cardiac sodium channel (SCN5A). SkM1 preserved conduction in the infarct border zone by increasing the maximum upstroke velocity of action potentials, reflected in situ by narrowing of wide or fragmented electrograms. Electrophysiological testing demonstrated that SkM1 administration significantly decreased the incidence of inducible ventricular tachyarrhythmias. This proof-ofconcept study provides evidence that preserving or increasing conduction velocity in the infarct border zone by focal delivery of a gene-based therapy such as overexpression of SkM1 is antiarrhythmic. Unlike traditional drugs, gene therapy interventions are not limited to targeting the native channels expressed by cardiomyocytes but allow delivery of foreign channels with more favorable biophysical properties.
Conclusions: SkM1 increases V 127 max of depolarized myocardium and reduces the incidence of inducible sustained ventricular tachyarrhythmia/fibrillation in canine infarcts. Gene therapy to normalize activation by increasing V 127 max at depolarized potentials may be a promising antiarrhythmic strategy. 29
Birth Weight Is a Significant Risk Factor for Incident Atrial Fibrillation
Summary: Although birth weight has been associated with the risk of coronary disease and stroke, few if any studies have assessed the influence of birth weight on the risk of developing atrial fibrillation. We prospectively followed up 27 982 women who were Ͼ45 years of age and free of cardiovascular disease and atrial fibrillation at baseline. Birth weight was categorized into 5 different categories: Ͻ2.5, 2.5 to 3.2, 3.2 to 3.9, 3.9 to 4.5, and Ͼ4.5 kg. We found that higher birth weight was associated with an increased risk of atrial fibrillation during adulthood. The 2 highest categories were associated with a 70% and 71% increased risk after multivariable adjustment. Further adjustment for adult height and maximum body weight in young adulthood substantially attenuated these findings. Our results therefore demonstrate that birth weight is significantly associated with incident atrial fibrillation among women. We believe that our findings also suggest that early life determinants may play an important role in the pathogenesis of atrial fibrillation. Most of this effect seems to be mediated through height and cumulative lifetime exposure to elevated body mass. In this context, the increasing prevalence of newborns with an elevated birth weight over the last decades might provide one explanation for the increasing AF burden in Western societies.
Conclusions: Birth weight is significantly associated with incident AF among women, suggesting that early life determinants may play an important role in the pathogenesis of AF. 30
Amino-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein as Predictors of Sudden Cardiac Death Among Women
Summary: Plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) predict risk of sudden cardiac death (SCD) in patients with known cardiac disease, but currently there are no data for SCD risk prediction in populations unselected on the basis of cardiac disease. In this nested case-control analysis within the 121 700-person Nurses' Health Study, 99 cases of definite or probable SCD were identified and matched to 294 controls on the basis of age, smoking, and prior cardiovascular disease. Baseline plasma NT-proBNP levels, but not C-reactive protein or lipid levels, were significantly associated with SCD using a multivariable model adjusted for coronary heart disease risk factors and other biomarkers. After multivariable adjustment, each 1-SD increment in log NT-proBNP was associated with an Ϸ50% increase in the risk of SCD, and levels above the prespecified cutpoint of 389 pg/mL were associated with a 5-fold increased risk of SCD. These findings offer potential insights into the pathophysiology underlying SCD in women. Specifically, they point to increased myocardial wall stress, along with associated left ventricular dilatation, hypertrophy, and/or fibrosis, as potential mediators of electric instability leading to SCD in women. The lack of association of other well-established coronary heart disease risk factors (including high-sensitivity C-reactive protein) suggests that mechanical-electric disturbances might play a greater role than undetected atherosclerosis in SCD risk among women. If confirmed in larger studies, marked elevations in NT-proBNP levels might also be useful in identifying women at higher risk for SCD many years before the fatal event.
Conclusions: In this population of women, baseline levels of NT-proBNP were associated with subsequent risk of SCD. If this association is confirmed in larger prospectively studied populations, these findings might provide another useful marker contributing to efforts to screen and prevent SCD among women. 31 has been a major cause of the withdrawal of medications from the market in the last decade. Recent studies in large human cohorts have suggested that many genes regulate the human QT interval, or cardiac repolarization. We and others have shown that cardiac repolarization in the zebrafish bears remarkable similarities to human physiology. We have developed techniques to study cardiac electrophysiology in the zebrafish and performed a genetic screen to aid in the discovery of new genes for repolarization. Using this approach, we confirmed that the recently identified NOS1AP gene regulates cardiac electrophysiological function and performed a drugsensitized screen for genes affecting repolarization. The results have revealed a network of 15 genes that modulate the response to the QT-prolonging drug dofetilide. One of the genes in this network, GINS3, also was recently found in independent human studies to be associated with QT variation. Identification of these genes may lead to a better understanding of the underlying biology, aid in identification of patients at risk for sudden death, and potentially enable new treatments for susceptible individuals.
Conclusions: This sensitized zebrafish screen identified 15 novel myocardial repolarization genes. Among these genes is GINS3, the human ortholog of which is a major locus in 2 concurrent human genome-wide association studies of QT interval. These results reveal a novel network of genes that regulate cardiac repolarization. 32
Bacterial Colonization and Infection of Electrophysiological Cardiac Devices Detected With Sonication and Swab Culture
Summary: In this study, we showed that bacteria can colonize electrophysiological devices without signs of infection. Because only a few of the patients with bacteria detected at the time of device removal developed an infection during follow-up, antibiotic treatment is probably not indicated in these patients. However, the role of colonizing bacteria in the development in infection must be further elucidated, and perioperative antibiotic prophylaxis with additional coverage of coagulase-negative staphylococci and Propionibacterium acnes should be evaluated. Additionally, we showed that bacteria on electrophysiological devices can be better detected with sonication than with conventional swab culture, suggesting that sonication of removed infected devices might be more sensitive in isolating bacteria, especially when patients are already receiving antibiotic treatment.
Conclusions: Bacteria can colonize cardiac electrophysiological devices without clinical signs of infection. 33
Selective Molecular Potassium Channel Blockade Prevents Atrial Fibrillation
Summary: Atrial fibrillation is the most common arrhythmia found in clinical practice, affecting 2 to 5 million people in the United States and several million more worldwide. The presence of atrial fibrillation substantially increases individual risk of stroke, heart failure, and death. A principal limitation to clinical practice is the lack of safe, effective therapies for this pervasive arrhythmia. We previously reported a gene-painting method capable of 100% transmural gene transfer to all parts of the atria accessible from an open-chest pericardium approach. In the present report, we used this method to transduce the atria with KCNH2-G628S, a mutation that blocks the rapid component of the delayed rectifier potassium current. This current is also blocked by class III antiarrhythmic drugs, but those drugs affect atrial and ventricular myocytes alike. The painting method is specific to atrial myocytes. We found that KCNH2-G628S gene transfer prolonged atrial action potential and prevented atrial fibrillation. This effect correlated with the time course of transgene expression. The method should be directly applicable to the problem of postoperative atrial fibrillation. With modifications to increase duration of gene expression and to reduce the invasive nature of delivery, the method should also be applicable to general atrial fibrillation. Formal preclinical testing is required before clinical investigation.
Conclusions: Gene therapy with KCNH2-G628S eliminated AF by prolonging atrial action potential duration. The effect duration correlated with transgene expression. 34 Conclusions: Marked regional endocardial conduction delay and heterogeneities in repolarization exist in BS. Wavebreak in areas of maximal conduction delay appears to be critical in the initiation and maintenance of ventricular tachycardia. These data indicate that further studies of mapping BS to identify slow-conduction zones should be considered to determine their role in spontaneous ventricular arrhythmias. 35
High-Density Substrate Mapping in Brugada Syndrome: Combined Role of Conduction and Repolarization Heterogeneities in Arrhythmogenesis
Spinal Cord Stimulation Improves Ventricular Function and Reduces Ventricular Arrhythmias in a Canine Postinfarction Heart Failure Model
Summary: Sudden cardiac arrest and heart failure (HF) are among the leading causes of morbidity and mortality in the industrialized world. The majority of pharmacological therapies available target symptoms or clinical manifestations rather than actually improve cardiac function. Implantable cardioverter-defibrillators and cardiac resynchronization therapy with defibrillation can improve survival but do not markedly improve cardiac function in the majority of patients receiving these therapies, and many patients progress to end-stage HF. At this point, therapeutic options to improve ventricular function include surgical placement of ventricular assist devices or cardiac transplantation. Cardiac transplantation is limited by the static supply of donor organs (currently 2500 to 3000 available per year). Importantly, the cost of these surgical treatments is high, and therefore they can only be offered to a small percentage of the patients who suffer from end-stage HF. This situation underscores the urgent need to develop novel and cost-effective therapies for the treatment of end-stage HF. The present work provides experimental evidence that neuromodulation using spinal cord stimulation (SCS) can significantly improve cardiac function and decrease the prevalence of lethal arrhythmias in a canine infarction and HF model.
Because SCS is a less-invasive and morbid therapy than standard surgical options, it may prove to be a novel and effective therapeutic option in the HF patient. Clinical trials are obviously needed to evaluate the safety and efficacy of SCS in human heart failure. If SCS proves to be an effective therapy for human HF, a new treatment paradigm may emerge for this difficult-to-treat patient population.
Conclusion: SCS significantly improved cardiac contractile function and decreased ventricular arrhythmias in canine heart failure. 36
Neuronal Nitric Oxide Synthase Protects Against Myocardial Infarction-Induced Ventricular Arrhythmia and Mortality in Mice
Summary: Ventricular arrhythmia is a common cause of death after myocardial infarction (MI). Cardiomyocyte Ca 2ϩ overload and diastolic Ca 2ϩ leak are important mechanisms responsible for afterdepolarization and triggered activity leading to ventricular arrhythmia after MI. Emerging evidence suggests that neuronal nitric oxide synthase (nNOS) may inhibit arrhythmogenesis by maintaining intracellular Ca 2ϩ homeostasis in cardiomyocytes. However, the role of nNOS in ventricular arrhythmia after MI in vivo is not clear.
In the present study, we demonstrated that nNOS deletion was associated with increased mortality, reactive oxygen species production, and apoptosis after MI. A novel finding from our study is that ventricular arrhythmias were significantly higher in nNOS -/compared with wild-type mice after MI. Deficiency in nNOS increased Ca 2ϩ transient amplitude and L-type Ca 2ϩ channel activity and increased diastolic Ca 2ϩ levels in cardiomyocytes. Lack of nNOS decreased S-nitrosylation of the L-type Ca 2ϩ channel, ryanodine receptor Ca 2ϩ release channel, and SERCA2 in the myocardium after MI. Thus, nNOS has a beneficial role in Ca 2ϩ homeostasis via S-nitrosylation of Ca 2ϩ handling proteins, leading to reductions in ventricular arrhythmias and death after MI. Our study provides new insights into the protective role of nNOS in arrhythmogenesis and may have therapeutic implications after MI.
Conclusions: Deficiency in nNOS increases ventricular arrhythmia and mortality after MI in mice. The antiarrhythmic effect of nNOS involves inhibition of L-type Ca 2ϩ channel activity and regulation of Ca 2ϩ handling proteins via S-nitrosylation. 37
NOS1AP Is a Genetic Modifier of the Long-QT Syndrome
Summary: Congenital long-QT syndrome (LQTS) is a type of heritable primary cardiac arrhythmia susceptibility disease and a known cause of sudden death, especially in young adults and children. Among those found to carry the same mutation, the probability of life-threatening cardiac events can vary considerably, leading to the hypothesis that genetic factors other than the primary disease-causing mutation may modify arrhythmic risk in LQTS. Common genetic variants in NOS1AP are associated with the QT-interval duration in the general population, and in this study, we tested whether NOS1AP variants modify the risk of clinical manifestations and the degree of QT-interval prolongation in members of a large South African LQTS population all carrying the same mutation (KCNQ1-A341V). We found that the minor alleles of 2 NOS1AP variants were associated with increased risk of lifethreatening events and with the probability of having a rate-corrected QT interval in the upper 40th percentile (Ͼ492 ms) of values in the study population. These observations indicate that NOS1AP is a genetic modifier of LQTS, and this knowledge should become clinically useful for risk stratification after validation in other LQTS populations.
Conclusions: These findings indicate that NOS1AP, a gene first identified as affecting the QTc interval in a general population, also influences sudden death risk in subjects with LQTS. The association of NOS1AP genetic variants with risk for life-threatening arrhyth-mias suggests that this gene is a genetic modifier of LQTS, and this knowledge may be clinically useful for risk stratification for patients with this disease, after validation in other LQTS populations. 38
Early Reperfusion During Acute Myocardial Infarction Affects Ventricular Tachycardia Characteristics and the Chronic Electroanatomic and Histological Substrate
Summary: Reperfusion therapy during acute myocardial infarction results in myocardial salvage. The duration of coronary artery occlusion and early reperfusion have been shown to affect the size and geometry of fibrosis after myocardial infarction. The 3-dimensional scar geometry influences reentry circuit location and ventricular tachycardia (VT) characteristics. Current substrate-based catheter ablation strategies for VT after myocardial infarction are based predominantly on studies in patients and animals with a chronically occluded infarct-related artery resulting in large homogeneous scars. In the present study, we demonstrate that early reperfusion influences the characteristics of post-acute myocardial infarction scars assessed by electroanatomic voltage mapping and by histology after myocardial infarction compared with patients without reperfusion therapy. Early reperfusion was associated with less dense and less confluent electroanatomic scars consisting of thicker layers of viable myocardium that appear to give rise to faster spontaneous and inducible VTs. These findings may have important implications for the management of patients in the reperfusion era who present with VTs. Poorly tolerated VT requires a substrate-based ablation approach. However, current substrate-based techniques relying on voltage and pace mapping to target the scar border zone may not be applicable for smaller, less dense, and less confluent scar. Whether these changes in the electroanatomic VT substrate of reperfused patients will pose a challenge in ablation needs further evaluation. Studies in animal models more realistic in the reperfusion era are warranted to reevaluate the relationship of the VT circuit and the architecture of the scar and to reassess substrate-based ablation concepts.
Conclusions: Scar size and pattern defined by electroanatomic mapping are different between VT patients with and without reperfusion during acute myocardial infarction. Less confluent electroanatomic scars match with thick layers of surviving myocardium on histology. Early reperfusion and less confluent electroanatomic scar are associated with faster VTs. 39
Regulation of the Human Cardiac Mitochondrial Ca 2؉ Uptake by 2 Different Voltage-Gated Ca 2؉ Channels
Summary: Impairment of intracellular Ca 2ϩ homeostasis and mitochondrial function has been implicated in the development of cardiomyopathy. Numerous studies have identified decreased cardiac energy levels and flux as consistent features of heart failure. The mitochondrial Ca 2ϩ uptake from the cytosol controls, among other things, the rate of energy production. Mitochondrial Ca 2ϩ sequestration is thought to be mediated by the Ca 2ϩ uniporter (MCU) and a thus far speculative non-MCU pathway. However, the identity and properties of these pathways are a matter of intense debate, and possible functional alterations in diseased states have remained elusive. By patch clamping the inner membrane of mitochondria from nonfailing and failing human hearts, we have demonstrated that human cardiac mitochondrial Ca 2ϩ uptake is regulated by 2 different selective Ca 2ϩ channels that we refer to as mCa1 and mCa2. Both channels are voltage gated and exhibit increased activity at more negative potentials, making them particularly sufficient for Ca 2ϩ uptake driven by the large electrochemical gradient for Ca 2ϩ across the inner membrane of energized mitochondria. The distinct biophysical and pharmacological properties of these 2 Ca 2ϩ channels support the notion that they underlie the human MCU and the non-MCU Ca 2ϩ uptake pathway, respectively. Notably, activity of mCa1 and mCa2 channels is decreased in failing compared with nonfailing heart conditions, making them less effective for Ca 2ϩ uptake and likely Ca 2ϩ -induced metabolism, which may explain, at least partly, reduced myocardial ATP levels in advanced heart failure.
Conclusions:
We conclude that the human mitochondrial Ca 2ϩ uptake is mediated by these 2 distinct Ca 2ϩ channels, which are functionally impaired in heart failure. Current properties reveal that the mCa1 channel underlies the human MCU and that the mCa2 channel is responsible for the ruthenium red-insensitive/lowsensitivity non-MCU-type mitochondrial Ca 2ϩ uptake. 40
Complications Associated With Revision of Sprint Fidelis Leads: Report From the Canadian Heart Rhythm Society Device Advisory Committee
Summary: It has been observed that implantable cardioverterdefibrillator generator replacement in response to a device advisory may be associated with a substantial rate of complications, including death. We sought to determine the risk of lead revision in response to a lead advisory, which has not been determined previously. Twenty-five implantable cardioverter-defibrillator implantation and follow-up centers from the Canadian Heart Rhythm Society Device Advisory Committee were surveyed to assess complications rates as a result of lead revision due to the Sprint Fidelis advisory issued in October 2007. Complications were encountered in 14.5% of the lead revisions. There were 2 deaths (0.43%). The overall risk of complications (19.8%) was greater among those who underwent lead removal at the time of revision than among those whose leads were abandoned (8.6%; Pϭ0.0008). The risk of complications associated with lead revision due to an advisory is significant. Given the increasing prevalence of lead fracture associated with this advisory (4.97%), however, revision at the time of pulse generator change or other intervention that results in opening of the pocket may be warranted. The present data suggest that lead abandonment at the time of revision may be associated with a lower complication rate. Further data on risk factors for lead fracture will be helpful in advising patients of the risk and benefit in replacing leads affected by an advisory.
Conclusions:
The overall rate of major complications that arose from lead revision due to the Sprint Fidelis advisory was significant. This must be taken into account when lead revision is planned in those patients who have not yet demonstrated an abnormality in lead performance. 41
Augmentation of Left Ventricular Contractility by Cardiac Sympathetic Neural Stimulation
Summary: During worsening of congestive heart failure, an intrinsic counterregulatory increase in humoral and neural sympathetic tone tries to compensate for the loss of ventricular contractility. This sympathetic hyperactivity might contribute to even more deterioration of heart failure. Antiadrenergic pharmacological ␤-receptor blocker therapy has been shown to decrease mortality in heart failure but cannot be applied to all patients because of systemic side effects like arterial hypotension and bradycardia. On the other hand, in the end stage of acute heart failure, catecholamine treatment is often needed to override ␤-receptor downregulation and to immediately augment left ventricular contractility. However, this is not cardioselective in that it also affects systemic vascular tone, thereby increasing cardiac afterload and potentially diminishing peripheral organ perfusion. This study provides experimental evidence for the presence of sympathetic neural fibers alongside the coronary sinus that selectively innervate the left ventricle and can be electrically stimulated by transvenously introduced electrode catheters. Because the obtained increase in left ventricular contractility is not accompanied by tachycardia or an increase in peripheral vascular resis-tance, such an approach might reduce the likelihood of peripheral organ damage. On the other hand, catheter ablation of the sympathetic nerves around the coronary sinus may be developed as a selective antiadrenergic therapy of the last resort in patients with severe ventricular arrhythmias (eg, to stabilize patients) during an electrical storm.
Conclusions: Cardiac nerve fibers that innervate the left ventricle are amenable to transvenous electric catheter stimulation. This may permit direct interference with and modulation of the sympathetic tone of the left ventricle. 42
Nonstaphylococcal Infections of Cardiac Implantable Electronic Devices
Summary: The number of infections of cardiac implantable electronic devices (CIEDs) continues to increase disproportionately to the increase in implantation rates. The average cost of combined medical-surgical treatment may surpass tens of thousands of dollars. Staphylococcal organisms account for 70% to 90% of all CIED infections. However, little is known about nonstaphylococcal organisms, which have been described only in case reports, in small case series, or combined in larger studies with staphylococcal CIED infections, thereby diluting the impact of nonstaphylococcal infections. Our study identified 504 patients with infection of a CIED, 80 (16%) of whom had a nonstaphylococcal infection. Although the demographics and comorbidities of subjects were comparable to those in other reports, our study illustrates many key points. First, the microbiological diversity of nonstaphylococcal infections was rather extensive because it included other Gram-positive bacteria like streptococci and enterococci, a variety of Gram-negative bacteria, atypical bacteria like Nocardia and Mycobacteria, and fungi like Candida and Aspergillus. Second, the duration of CIED insertion before nonstaphylococcal infection was relatively prolonged (mean, 109Ϯ27 weeks). Third, nonstaphylococcal organisms appear to be less virulent, cause prolonged clinical symptoms before admission (mean, 48Ϯ12.8 days), and are associated with lower mortality (4%). Fourth, contrary to prior reports, Gram-negative bloodstream infections could cause secondary seeding of the CIED. Finally, inappropriate antimicrobial coverage was provided in Ϸ50% of nonstaphylococcal infections for a mean period of 2.1 day. These findings should enhance our appreciation of the unique attributes of nonstaphylococcal infections of CIEDs. Strain was assessed along the longitudinal axis, predominantly representing subendocardial fibers, and along the circumferential axis, representing midmyocardial fibers. This study shows that LQTS patients have abnormal LV contraction patterns. Contraction duration was longer and more heterogeneous in symptomatic LQTS mutation carriers compared with asymptomatic patients. In addition, contraction duration was longer in the subendocardium than in the midmyocardium, indicating a pronounced transmural mechanical dispersion that was not present in asymptomatic and healthy individuals. Our findings suggest that echocardiography might be a complementary tool to QTc and may provide added value in risk stratification of LQTS mutation carriers.
Conclusions
Conclusion: Contraction duration in symptomatic LQTS mutation carriers was longer in the subendocardium than in the midmyocardium, indicating transmural mechanical dispersion, which was not present in asymptomatic and healthy individuals. 45
Neuraxial Modulation for Refractory Ventricular Arrhythmias: Value of Thoracic Epidural Anesthesia and Surgical Left Cardiac Sympathetic Denervation
Summary: Refractory ventricular arrhythmias represent a lifethreatening acute-care emergency and pose a major therapeutic challenge. Our study reports the effect of modulating cardiac sympathetic output from the neuraxis with thoracic epidural anesthesia and left cardiac sympathetic denervation for the management of refractory arrhythmias. Our observation suggests that control of serious arrhythmias can be approached in a stepwise fashion. The majority of patients presenting with malignant ventricular arrhythmias respond to a combination of ␤-blockade, antiarrhythmic drugs, and catheter ablation; however, in a subset of patients (such as the patients represented in this study), arrhythmias remain refractory.
Additional therapeutic strategies such as thoracic epidural anesthesia and left cardiac sympathetic denervation could be considered in this setting. In our study, these procedures were well tolerated, without serious complications. Thoracic epidural anesthesia can be performed at the bedside; it can be used as a bridge to catheter ablation, cardiac transplantation, and left cardiac sympathetic denervation. Left cardiac sympathetic denervation can be performed in an acute setting if it is readily available when no further ablative or surgical options exist or as a bridge to nonurgent cardiac transplantation. Our findings are retrospective and will need further evaluation in prospective, randomized studies.
Conclusions: Initiation of thoracic epidural anesthesia (TEA) and left cardiac sympathetic denervation (LCSD) in patients with refractory VT was associated with a subsequent decrease in arrhythmia burden in 6 (75%) of 8 patients (68% confidence interval 51% to 91%) and 5 (56%) of 9 patients (68% confidence interval 34% to 75%), respectively. These data suggest that TEA and LCSD may be effective additions to the management of refractory ventricular arrhythmias in structural heart disease when other treatment modalities have failed or may serve as a bridge to more definitive therapy. 46
Electropathological Substrate of Longstanding Persistent Atrial Fibrillation in Patients With Structural Heart Disease: Epicardial Breakthrough
Summary: During the last years, several studies have questioned the validity of the multiple wavelet mechanism as the underlying mechanism of persistent atrial fibrillation (AF) in humans. More and more investigators tended to believe that a single source of rapid impulses, either a rotor or an automatic focus, acted as a "driver" that maintained AF. The difference is of considerable clinical significance because in cases of multiple dissociated waves, extensive ablation procedures consisting of several long transmural lesions are necessary to terminate the arrhythmia. In contrast, "focal" AF should be curable by a single ablation at the spot of the driving focus. In the present study in 24 patients with valvular disease and longstanding persistent AF, extensive mapping of the whole epicardial surface of right and left atria (except the Bachmann bundle), failed to exhibit any stable rotors or foci that could have perpetuated the arrhythmia. However, the most striking difference with acutely induced AF in patients with normal sinus rhythm was an almost 4-fold higher incidence of epicardial breakthrough. These breakthroughs occurred over the entire atrial wall, emerged at multiple sites, but as a rule were not repetitive. They are considered transmural reentry points of multiple wavelets propagating through the dissociated endocardial and epicardial layers of the atrial wall. The high persistence of AF in patients with valvular disease is caused by a process of endocardialepicardial dissociation that has turned the atrial wall into a 3-dimensional medium for multiple wavelets. Once fully developed, such a substrate of AF does not seem to be amenable anymore to a limited ablation procedure.
Conclusions: Focal fibrillation waves are due to epicardial breakthrough of waves propagating in deeper layers of the atrial wall. In patients with longstanding AF, the frequency of epicardial breakthroughs was 4 times higher than during acute AF. Because they provide a constant source of independent fibrillation waves originating over the entire epicardial surface, they offer an adequate explanation for the high persistence of AF in patients with structural heart disease. 47
Mechanisms by Which Adenosine Restores Conduction in Dormant Canine Pulmonary Veins
Summary: Ablation procedures are becoming an increasingly important therapeutic option for atrial fibrillation, particularly the paroxysmal form. A major limitation to such procedures is arrhythmia recurrence, often attributable to recurrent pulmonary-vein conduction, or so-called "reconnection." Intravenous adenosine administration at the time of an ablation procedure can cause acute pulmonaryvein reconnection, revealing "dormant" conduction, and is sometimes used as a test of the ability of veins to undergo later reconnection to guide additional ablation lesions. This experimental study aimed to clarify the unknown mechanism by which adenosine reveals dormant conduction. Arterially perfused canine left atrial/ pulmonary vein preparations were exposed to adenosine and radiofrequency ablation during action-potential and extracellularelectrode monitoring. Adenosine alone selectively hyperpolarized pulmonary-vein cardiomyocytes sleeves, increased their phase 0 upstroke velocity, and accelerated pulmonary vein/left atrial conduc-tion. Radiofrequency ablation to the antral region adjacent to the pulmonary vein/left atrial junction produced pulmonary vein/left atrial conduction block and depolarized pulmonary-vein cardiomyocytes near the ablation line. Adenosine caused acute reconnection by hyperpolarizing damaged pulmonary-vein cells sufficiently to restore excitability. Similar phenomena occurred spontaneously in some veins during a prolonged (mean 3-hour) observation period. Adenosine effects were reversible on washout, and adenosineexposed dormant conduction was a good predictor of subsequent spontaneous reconnection in the same vein. Voltage-clamp experiments suggested that the primary ionic-current mediator of adenosine's actions was adenosine-induced inward-rectifier potassium current. These studies provide insights into the mechanisms by which adenosine acutely restores pulmonary vein/left atrial conduction after radiofrequency ablation, with potential implications for our understanding of mechanisms of pulmonary-vein disconnection and reconnection.
Conclusions: Adenosine selectively hyperpolarizes canine pulmonary veins (PVs) by increasing I KAdo . PVs with dormant conduction show less radiofrequency-induced depolarization than nondormant veins, allowing adenosine-induced hyperpolarization to restore excitability by removing voltage-dependent I Na inactivation and explaining the restoration of conduction in dormant PVs. 48
Paradigm of Genetic Mosaicism and Lone Atrial Fibrillation: Physiological Characterization of a Connexin 43-Deletion Mutant Identified From Atrial Tissue
Summary: Atrial fibrillation is the most common sustained cardiac arrhythmia and is a common cause of stroke. Epidemiological studies project an exponential rise in the prevalence of atrial fibrillation in Western societies, coincident with the increasing age of the population. Management strategies for atrial fibrillation are not highly efficacious. Pharmacological therapies may lead to intolerable side effects and often become refractory over time. Success rates from catheter ablation procedures vary considerably between institutions and may lead to major complications, and long-term success (Ͼ24 months) in large cohorts has not been reported despite the use of this procedure for more than a decade. Thus, a further understanding of the molecular mechanisms promoting vulnerability to fibrillation of the atria is critical in facilitating the development of more efficacious therapies. In this study, we provide data implicating a loss-of-function mutation in the gene encoding the gap junction protein connexin 43 as a mechanism leading to augmentation of heterogeneous myocardial electric coupling, predisposing atrial myocardium to reentrant arrhythmias. Specific drug development enhancing gap junction function may attenuate arrhythmia vulnerability.
Conclusions: This study reports atrial tissue genetic mosaicism of a novel loss-of-function Cx43 mutation associated with lone AF. These findings implicate somatic genetic defects of Cx43 as a potential cause of AF and support the paradigm that sporadic, nonfamilial cases of lone AF may arise from genetic mosaicism that creates heterogeneous coupling patterns, predisposing the tissue to reentrant arrhythmias. 49
Factors Associated With Pulseless Electric Activity versus Ventricular Fibrillation: The Oregon Sudden Unexpected Death Study
Summary: In this population-based study, details of preexisting clinical conditions were combined with emergency medical services data to identify correlates of pulseless electric activity versus ventricular fibrillation and asystole. As expected, cases of cardiac arrest that presented with pulseless electric activity were significantly less likely to survive, and age, black race, female gender, and pulmonary disease were significant correlates of pulseless electric activity. As anticipated, ventricular fibrillation was more likely to be associated with a diagnosis of hyperlipidemia or coronary artery disease. However, there were no differences in the overall disease burden or resuscitation response time that explained occurrence of pulseless electric activity. In addition to reporting specific clinical correlates of pulseless electric activity, this study has identified a novel and significant association between lifetime syncope and future pulseless electric activity that was not explained by a higher prevalence of cardiac conduction system disease on the resting 12-lead ECG. Given the well-established rising prevalence of pulseless electric activity and significantly worse survival outcome compared with ventricular fibrillation, enhancing the mechanistic understanding of pulseless electric activity is a high priority. These findings, particularly the potential link between syncope and pulseless electric activity, are likely to provide a basis for new investigative approaches to evaluate mechanisms of this condition.
Conclusions: Pulseless electric activity (PEA) cases had a significantly higher prevalence of syncope in their lifetime, with other correlates, including black race, that were distinct from VF cases. Potential mechanistic links between syncope and future manifestation with PEA warrant further exploration. 50 
